Estimates Revisions Chugai Pharmaceutical Co., Ltd.

Equities

Market Closed - Japan Exchange Other stock markets 07:30:00 17/04/2026 BST			5-day change	1st Jan Change
8,349.00 ^JPY	-2.82%		-3.76%	+1.29%

04-16	Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk	CI
04-09	Foundayo? (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	CHUGAI PHARMACEUTICAL CO., LTD.
	ELI LILLY AND COMPANY
	JOHNSON & JOHNSON
	ABBVIE INC.
	ROCHE HOLDING AG			-
	ASTRAZENECA PLC
	MERCK & CO., INC.
	NOVARTIS AG
	AMGEN INC.
	NOVO NORDISK A/S
	Average
	Weighted average by Cap.